These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3067714)

  • 1. Immunological diagnosis of rejection in heart transplant recipients.
    Molajoni ER; Cinti P; Bachetoni A; Sallusto F; Caricato M; Mancini C; Mazzesi G; Marino B; Alfani D; Cortesini R
    Bibl Cardiol; 1988; (43):142-5. PubMed ID: 3067714
    [No Abstract]   [Full Text] [Related]  

  • 2. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appearance of cells bearing the interleukin-2 receptor in peripheral blood of cardiac transplant patients and their correlation with rejection episodes.
    Coles M; Rose M; Yacoub M
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2546-7. PubMed ID: 3274559
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring of renal transplant patients with interleukin-2 and interleukin-2 receptor enzyme immunoassay and interleukin-2 receptor immunocytology.
    Dittmer R; Harfmann P; Tenschert W; Arndt R; Busch B
    Transplant Proc; 1990 Oct; 22(5):2284-5. PubMed ID: 2219370
    [No Abstract]   [Full Text] [Related]  

  • 5. Relevance of immunological parameters to detect allograft rejection in heart transplant recipients.
    Renna Molajoni E; Bachetoni A; Cinti P; Sallusto F; Alfani D; Macchiarelli A; Scibilia G; Cassisi A; Marino B; Cortesini R
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2534-6. PubMed ID: 2650326
    [No Abstract]   [Full Text] [Related]  

  • 6. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
    Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
    Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lymphocyte subpopulations in cyclosporine-treated human heart rejection.
    Weintraub D; Masek M; Billingham ME
    J Heart Transplant; 1985 Feb; 4(2):213-6. PubMed ID: 3916488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with a monoclonal interleukin-2 receptor antibody (BT 563) for rejection therapy after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Freigassner M; Auer T; Kleinert R; Wasler A; Petutschnigg B; Müller H
    Transplant Proc; 1994 Dec; 26(6):3237-9. PubMed ID: 7998128
    [No Abstract]   [Full Text] [Related]  

  • 10. Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients.
    George JF; Kirklin JK; Naftel DC; Bourge RC; White-Williams C; McGiffin DC; Savunen T; Everson MP
    J Heart Lung Transplant; 1997 Oct; 16(10):1046-53. PubMed ID: 9361247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
    van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
    Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease.
    Kerman RH; Susskind B; Kerman D; Lam M; Gerolami K; Williams J; Kalish R; Campbell M; Katz S; Van Buren CT; Frazier H; Radovancevic B; Fife S; Kahan B
    J Heart Lung Transplant; 1998 Aug; 17(8):789-94. PubMed ID: 9730428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin 2 receptor level in liver allograft recipients: an indicator of rejection.
    Perkins JD; Nelson DL; Rakela J; Grambsch PM; Krom RA
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2275-6. PubMed ID: 2540568
    [No Abstract]   [Full Text] [Related]  

  • 14. Heart transplantation in females: the experience in Puerto Rico.
    Banchs HL; González V; González Cancel I; Quintana C; Calderón R; Altieri PI
    Bol Asoc Med P R; 2005; 97(4):248-56. PubMed ID: 16599066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of basement membrane antigens and of soluble interleukin 2 receptor serum concentrations in heart transplant rejection.
    Gabrielli A; Marrozzini C; Candela M; Ferretti RM; Recchioni A; Binetti GF; Danieli G
    Cardiologia; 1994 Jul; 39(7):481-6. PubMed ID: 7982245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation.
    Zwirska-Korczala K; Zakliczyński M; Berdowska A; Zembala M; Jochem J; Gajewska K
    J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of early and late activation markers on peripheral blood T lymphocytes does not reliably reflect immune events in transplanted hearts.
    Loertscher R; Forbes RD; Halabi G; Lavery P; Quinn T
    Clin Transplant; 1994 Jun; 8(3 Pt 1):230-8. PubMed ID: 8061361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 receptor expression in renal biopsies and the diagnosis of acute allograft rejection.
    Mathan A; Kuruvilla S; Abraham G
    Indian J Pathol Microbiol; 2006 Jan; 49(1):12-6. PubMed ID: 16625964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin-2 receptor (sIL-2R) levels in renal transplantation: comparison between clinical and laboratory analysis.
    Montagnino G; Tarantino A; Grignani S; Braga M; Ponticelli C
    Clin Transplant; 1995 Feb; 9(1):25-30. PubMed ID: 7742579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.